Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234362 · ClinicalTrials.gov registry record · Phase 4
Vortioxetine for Menopausal Depression
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 47
- Enrollment target
NCT02234362: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT02234362 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02234362, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 47 participants
- Enrollment target
Study Summary
The broad goal of this study was to examine the efficacy and tolerability of vortioxetine (flexible dose) for the treatment of major depressive disorder (MDD) in symptomatic women around the menopausal transition. We hypothesized that an eight-week treatment with vortioxetine would promote a significant improvement of depression symptoms and other menopause-related physical symptoms.
Interventions
- DRUG vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-06-12 |
| Est. Completion | 2016-09-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02234362
The ClinicalTrials.gov registry entry for NCT02234362 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vortioxetine is the first listed.
NCT02234362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02234362 about?
NCT02234362 is a clinical study titled "Vortioxetine for Menopausal Depression". The broad goal of this study was to examine the efficacy and tolerability of vortioxetine (flexible dose) for the treatment of major depressive disorder (MDD) in symptomatic women around the menopausal transition. We hypothesized that an eight-week treatment with vortioxetine would promote a signifi...
What is the current status of trial NCT02234362?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 47 participants. The study started on 2015-06-12. Estimated completion is 2016-09-29.
What interventions are being tested in trial NCT02234362?
The interventions under investigation include: vortioxetine (DRUG).
Who is sponsoring clinical trial NCT02234362?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.